Derazantinib
DZB-CS-202
Phase 2 small_molecule terminated
Quick answer
Derazantinib for Gastric Adenocarcinoma is a Phase 2 program (small_molecule) at Basilea Pharmaceutica with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Basilea Pharmaceutica
- Indication
- Gastric Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated